Increased prevalence of insulin resistance in patients with differentiated thyroid carcinoma

Metabolic Syndrome and Related Disorders

Volumn 7, Issue 4, 2009, Pages 375-380

  Rezzónico, Jorge N ^a   Rezzónico, Mariana ^a   Pusiol, Eduardo ^a   Pitoia, Fabian ^b   Niepomniszcze, Hugo ^b  

^a Centro Privado de Endocrinologia   (Argentina)

^b UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN; LIOTHYRONINE; THYROTROPIN; THYROXINE;

ADULT; ARTICLE; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HOMEOSTASIS MODEL ASSESMENT OF INSULIN RESISTANCE; HUMAN; HUMAN CELL; HUMAN TISSUE; INSULIN RESISTANCE; PREVALENCE; PRIORITY JOURNAL; THYROID CARCINOMA; THYROID FOLLICULAR CARCINOMA; THYROID NODULE; THYROID PAPILLARY CARCINOMA; TISSUE DIFFERENTIATION;

ANTHROPOMETRY; BLOOD PRESSURE; BODY MASS INDEX; CARCINOMA; FEMALE; HOMEOSTASIS; HUMANS; INSULIN; INSULIN RESISTANCE; MALE; OBESITY; OVERWEIGHT; PREVALENCE; REGISTRIES; RETROSPECTIVE STUDIES; RISK FACTORS; THYROID NEOPLASMS;

EID: 68549090727     PISSN: 15404196     EISSN: None     Source Type: Journal    
DOI: 10.1089/met.2008.0062     Document Type: Article

References (50)

1. Reaven GM. Role of insulin resistance in human disease. Diabetes 1988;37:1595-1607.
2. Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Bodymass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 2008:371:569-578. (Pubitemid 351232031)
3. Ascaso JF ,Pardo S, Real JT, Lorente RI, Priego A, Carmena R. Diagnosing insulin resistance by simple quantitative methods in subjects with normal glucose metabolism. Diabetes Care 2003;26:3320-3325. (Pubitemid 37466894)
4. Rojo-Martinez G, Esteva I, de Adana SR, Catala M, Merelo MJ, Tinahones F, Gomez-Zumaquero JM, Cuesta AL, Cardona F, Soriguer F. Patterns of insulin resistance in the general population of southeast Spain. Diabetes Res Clin Pract 2004;65:247-256. (Pubitemid 39141181)
5. Kahn SE. The importance of the beta-cell in the pathogenesis of type 2 diabetes mellitus. Am J Med 2000;108:2S-8S.
6. Abbasi F, Brown BW Jr, Lamendola C, McLaughlin T, Reaven GM. Relationship between obesity, insulin resistance, and coronary heart disease risk. J Am Coll Cardiol 2002;40:937-943. (Pubitemid 34994988)
7. McLaughlin T, Abbasi F, Lamendola C, Liang L, Reaven G, Schaaf P, Reaven P. Differentiation between obesity and insulin resistance in the association with C-reactive protein. Circulation 2002;106: 2908-2912. (Pubitemid 35424740)
8. McLaughlin T, Allison G, Abbasi F, Lamendola C, Reaven G. Prevalence of insulin resistance and associated cardiovascular disease risk factors among normal weight, overweight, and obese individuals. Metabolism 2004;53:495-499. (Pubitemid 38419194)
9. Ford ES, Mokdad AH, Giles WH. Trends in waist circumference among U.S. adults. Obes Res 2003;11:1223-1231.
10. Hedley AA, Ogden CL, Johnson CL, Carroll MD, Curtin LR, Flegal KM. Prevalence of overweight and obesity among US children, adolescents, and adults, 1999-2002. JAMA 2004;291:2847-2850.
11. Rezzonico J, Rezzonico M, Pusiol E, Pitoia F, Niepomniszcze H. Introducing the thyroid gland as another victim of the insulin resistance syndrome. Thyroid 2008;18:461-464.
12. Saborido L, Latres de Rauek B, Rezzonico JN, Guntsche Z, Cabut V, Leiva R, Munoz P, Bidot L, Vitoria C, Rosso A. Iodine in schoolchildren. Relationship with incidence of goiter, socioeconomic group and salt intake. Medicina (B Aires) 1996;56:448-454. (Pubitemid 127540501)
13. Galvin P, Wa rd G, Walters J, Pestell R, Koschmann M, Vaag A, Martin I, Best JD, A l f o rd F. A simple method for quantitation of insulin sensitivity and insulin release from an intravenous glucose tolerance test. Diabet Med 1992;9:921-928.
14. Brunn J, Block U, Ruf G, Bos I, Kunze WP, Scriba PC. Volumetric analysis of thyroid lobes by real-time ultrasound. Dtsch Med Wochenschr 1981;106:1338-1340.
15. Li C, Ford ES, McGuire LC, Mokdad AH, Little RR, Reaven GM. Trends in hyperinsulinemia among nondiabetic adults in the U.S. Diabetes Care 2006;29:2396-2402. (Pubitemid 44912242)
16. Reaven GM. Banting Lecture 1988: Role of insulin resistance in human disease. Diabetes 1988;37:1595-1607.
17. Reaven G. The metabolic syndrome or the insulin resistance syndrome? Different names, different concepts, and different goals. Endocrinol Metab Clin North Am 2004;33:283-303. (Pubitemid 38680631)
18. Marchisotti FG, Umeda LM, Zach PL, Saldanha MD, First OS, Liberman B. Acromegaly and thyroid disease: Prevalence of thyroid cancer. Arq Bras Endocrinol Metabol 2005;49:843-849.
19. Tita P, Ambrosio MR, Scollo C, Carta A, Gangemi P, Bondanelli M, Vigneri R, degli Uberti EC, Pezzino V. High prevalence of differentiated thyroid carcinoma in acromegaly. Clin Endocrinol (Oxf) 2005;63:161-167.
20. Nelson WG, De Marzo AM, DeWeese TL, Isaacs WB. The role of inflammation in the pathogenesis of prostate cancer. J Urol 2004;172(5 Pt 2):S6-S11.
21. Kaaks R, Lukanova A, Sommersberg B. Plasma androgens, IGF-1, body size, and prostate cancer risk: a synthetic review. Prostate Cancer Prostatic Dis 2000;3:157-172
22. Ciampolillo A, De Tullio C, Giorgino F. The IGF-I/IGF-I receptor pathway: Implications in the Pathophysiology of Thyroid Cancer. Curr Med Chem 2005;12:2881-2891. (Pubitemid 41613364)
23. Werner H, Le Roith D. The insulin-like growth factor-I receptor signaling pathways are important for tumorigenesis and inhibition of apoptosis. Crit Rev Oncog 1997;8:71-92. (Pubitemid 28131305)
24. LeRoith D, Roberts CT Jr: The insulin-like growth factor system and cancer. Cancer Lett 2003;95:127-137. (Pubitemid 36588961)
25. Maiorano E, Ciampolillo A, Viale G, Maisonneuve P, Ambrosi A, Triggiani V, Marra E, Perlino E. Insulin-like growth factor 1 expression in thyroid tumors. Appl Immunohistochem Mol Morphol 2000;8:110-119. (Pubitemid 30609971)
26. Fu P, Thompson JA, Leeding KS, Bach LA. Insulin-like growth factors induce apoptosis as well as proliferation in LIM 1215 colon cancer cells. J Cell Biochem 2007;100:58-68. (Pubitemid 44958179)
27. Platz EA, De Marzo AM. Epidemiology of inflammation and prostate cancer. J Urol 2004;171:S36-S40.
28. Sun J, Hsu FC, Turner AR, et al. Meta-analysis of association of rare mutations and common sequence variants in the MSR1 gene and prostate cancer risk. Prostate 2006;66:728-737.
29. Xu J, Lowey J, Wiklund F, et al. The interaction of four genes in the inflammation pathway significantly predicts prostate cancer risk. Cancer Epidemiol Biomarkers Prev 2005;14:2563-2568. (Pubitemid 41752716)
30. Lindmark F, Zheng SL, Wiklund F, et al. Interleukin-1 receptor antagonist haplotype associated with prostate cancer risk. Br J Cancer 2005;93:493-497. (Pubitemid 43080026)
31. Greenberg AS, Obin MS. Obesity and the role of adipose tissue in inflammation and metabolism. Am J Clin Nutr 2006;83:461S-465S.
32. Dandona P, Aljada A, Chaudhuri A, Mohanty P, Garg R. Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and inflammation. Circulation 2005;111:1448-1454. (Pubitemid 40396812)
33. Ghanim H, Aljada A, Daoud N, Deopurkar R, Chaudhuri A, Dandona P. Role of inflammatory mediators in the suppression of insulin receptor phosphorylation in circulating mononuclear cells of obese subjects. Diabetologia 2007;50:278-285.
34. Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest 2006;116:1793-1801.
35. Fradet V, Lessard L, Begin LR, Karakiewicz P, Masson AM, Saad F. Nuclear factor-kappaB nuclear localization is predictive of biochemical recurrence in patients with positive margin prostate cancer. Clin Cancer Res 2004;10:8460-8464. (Pubitemid 40053410)
36. Lessard L, Begin LR, Gleave ME, Mes-Masson AM, Saad F. Nuclear localisation of nuclear factor-kappaB transcription factors in prostate cancer: An immunohistochemical study. Br J Cancer 2005;93:1019-1023. (Pubitemid 41548396)
37. Domingo-Domenech J, Mellado B, Ferrer B, et al. Activation of nuclear factor-kappaB in human prostate carcinogenesis and association to biochemical relapse. Br J Cancer 2005;93:1285-1294. (Pubitemid 41679415)
38. Sha WC, Liou HC, Tuomanen EI, Baltimore D. Targeted disruption of the p50 subunit of NF-kappa B leads to multifocal defects in immune responses. Cell 1995;80:321-330.
39. Dandona P, Aljada A, Mohanty P, Ghanim H, Hamouda W, Assian E, Ahmad S. Insulin inhibits intranuclear nuclear factor kappaB and stimulates IkappaB in mononuclear cells in obese subjects: evidence for an anti-inflammatory effect? J Clin Endocrinol Metab 2001;86:3257-3265 (Pubitemid 32674120)
40. Mitchell I, Livingston EH, Chang AY, Holt S, Snyder WH 3rd, Lingvay I, Nwariaku FE. Trends in thyroid cancer demographics and surgical therapy in the United States. Surgery 2007;142:823-828.
41. Bounacer A, Wicker R, Caillou B, Cailleux AF, SaRasin A, Schlumberger M, Suarez HG. High prevalence of activating ret proto-oncogene rearrangements, in thyroid tumors from patients who had received external radiation. Oncogene 1997;15:1263-1273. (Pubitemid 27429741)
42. Grieco M, Santoro M, Berlingieri MT, Melillo RM, Donghi R, Bongarzone I, Pierotti MA, Della Porta G, Fusco A, Vecchio G. PTC is a novel rearranged form of the ret protooncogene and is frequently detected in vivo in human thyroid papillary carcinomas. Cell 1990;60:557-563. (Pubitemid 20083812)
43. Wajjwalku W, Nakamura S, Hasegawa Y, Miyazaki K, Satoh Y, Funahashi H, Matsuyama M, Takahashi M. Low frequency of rearrangements of the ret and trk proto-oncogenes in Japanese thyroid papillary carcinomas. Jpn J Cancer Res 1992;83:671-675.
44. Santoro M, Thomas GA, Vecchio G, Williams GH, Fusco A, Chiappetta G, Pozcharskaya V, Bogdanova TI, Demidchik EP, Cherstvoy ED, Voscoboinik L, Tronko ND, Carss A, Bunnell H, Tonnachera M, Parma J, Dumont JE, Keller G, Hofler H, Williams ED. Gene rearrangement and Chernobyl related thyroid cancers. Br J Cancer 2000;82:315-322.
45. Challeton C, Bounacer A, Du Villard JA, Caillou B, De Vathaire F, Monier R, Schlumberger M, Suarez HG. Pattern of Ras and gsp oncogene mutations in radiation-associated human thyroid tumors. Oncogene 1995;11:601-603.
46. Lemoine NR, Mayall ES, Wyllie FS, Williams ED, Goyns M, Stringer B, Wynford-Thomas D. High frequency of Ras oncogene activation in all stages of human thyroid tumorigenesis. Oncogene 1989;4:159-164. (Pubitemid 19096939)
47. Esapa C, Johnson SJ, Kendall-Taylor P, Lennard TWJ, Harris P. Prevalence of Ras mutations in thyroid neoplasia. Clin Endocrinol (Oxf) 1999;50:529-535. (Pubitemid 29193238)
48. Cohen Y, Xing M, Mambo E, Guo Z, Wu G, Trink B, Beller U, Westra WH, Ladenson PW, Sidransky D. BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst 2003;95:625-627. (Pubitemid 36553510)
49. Namba H, Nakashima M, Hayashi T, Hayashida N, Maeda S, Rogounovitch TI, Ohtsuru A, Saenko VA, Kanematsu T, Yamashita S. Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. J Clin Endocrinol Metab 2003;88:4393-4397. (Pubitemid 37153748)
50. Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/ PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 2003;63:1454-1457. (Pubitemid 36373628)